Skip to main content
Clinical Trials/ITMCTR2022000018
ITMCTR2022000018
Not yet recruiting
Phase 1

Evaluation of the therapeutic effect of integrated traditional Chinese and western medicine on macular edema of central retinal vein occlusion

Eye hospital of Chinese Academy of Chinese Medical Sciences0 sitesTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Eye hospital of Chinese Academy of Chinese Medical Sciences
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Eye hospital of Chinese Academy of Chinese Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • (1\) Age: 30 and 75 years old;
  • (2\) Meet the diagnostic criteria for western medicine diagnosis of macular edema of central retinal vein obstruction in the diagnostic criteria and the diagnostic criteria of sputum and blood stasis syndrome syndrome;
  • (3\) Patients who voluntarily participate in the project study and have good compliance.

Exclusion Criteria

  • (1\) Combined with keratitis, endophthalmitis and other active bacteria, viruses, fungal infections;
  • (2\) With macular hole, central serous chororetinopathy, diabetic retinopathy, retinopathy, retinal pigmentosa, and other fundus diseases affecting retinal detachment;
  • (3\) Combined with the refractive interstitial turbidity, and unable to complete the FFA or OCT inspection;
  • (4\) Whole\-body or eye conditions are not suitable for room water extraction and testing;
  • (5\) Allergic to leezumab, fluorescein sodium contrast agent, or allergic to the components of the formula;
  • (6\) Suffering from serious heart, brain, liver, kidney, blood system and other systemic diseases;
  • (7\) With neurological and mental disorders, unable to cooperate or unwilling to cooperate;
  • (8\) Pregnant or lactating women or those with recent family plans;
  • (9\) Those who have participated in other clinical trials 3 months before selection, or other circumstances that the investigator considers unsuitable to participate in this trial.

Outcomes

Primary Outcomes

Not specified

Similar Trials